Reports and Reviews For: (OTCQB: TTNP), (OTC Pink: OGXPY)
Titan Pharmaceuticals Inc. (OTCQB: TTNP) announced that the Psychopharmacologic Drugs Advisory Committee (PDAC) of the U.S. Food and Drug Administration (FDA) is scheduled to review the Company's New Drug Application (NDA) for Probuphine® for the maintenance treatment of adult patients with opioid dependence on March 21, 2013.
View full press release